XOMA Corp (NASDAQ:XOMA) CEO James R. Neal acquired 4,000 shares of the business’s stock in a transaction dated Tuesday, November 13th. The stock was acquired at an average price of $13.26 per share, for a total transaction of $53,040.00. Following the completion of the transaction, the chief executive officer now owns 20,333 shares in the company, valued at approximately $269,615.58. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of XOMA traded up $0.12 on Thursday, reaching $13.53. The stock had a trading volume of 90,925 shares, compared to its average volume of 131,731. The stock has a market cap of $120.19 million, a PE ratio of 13.81 and a beta of 2.75. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 19.16. XOMA Corp has a 12-month low of $11.88 and a 12-month high of $37.25.
XOMA (NASDAQ:XOMA) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.40). The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.83 million. XOMA had a negative net margin of 129.85% and a negative return on equity of 267.64%. Equities analysts anticipate that XOMA Corp will post -1.26 EPS for the current year.
A number of equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of XOMA in a research report on Friday, September 21st. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of XOMA in a research report on Wednesday, August 8th. ValuEngine lowered XOMA from a “hold” rating to a “sell” rating in a research report on Friday, September 7th. Zacks Investment Research lowered XOMA from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. Finally, Cowen restated a “hold” rating on shares of XOMA in a research note on Thursday, November 8th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $28.07.
Several institutional investors and hedge funds have recently added to or reduced their stakes in XOMA. BlackRock Inc. lifted its stake in shares of XOMA by 151.6% in the 2nd quarter. BlackRock Inc. now owns 448,856 shares of the biotechnology company’s stock valued at $9,373,000 after purchasing an additional 270,437 shares during the period. Northern Trust Corp lifted its stake in shares of XOMA by 308.6% in the 2nd quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock valued at $1,424,000 after purchasing an additional 51,510 shares during the period. Acadian Asset Management LLC lifted its stake in shares of XOMA by 70.4% in the 2nd quarter. Acadian Asset Management LLC now owns 96,051 shares of the biotechnology company’s stock valued at $2,006,000 after purchasing an additional 39,672 shares during the period. Strs Ohio purchased a new position in shares of XOMA in the 2nd quarter valued at approximately $680,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of XOMA in the 2nd quarter valued at approximately $631,000. Institutional investors own 43.45% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://macondaily.com/2018/11/15/xoma-corp-xoma-ceo-james-r-neal-acquires-4000-shares.html.
XOMA Company Profile
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.